Pfizer Canada Initiates Submission to Health Canada for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine
Indications under review include prevention of RSV in infants from birth through 6 months of age by immunization of pregnant individuals, and in individuals 60 years of age and older…. Read More

